Mezigdomide

The combination of mezigdomide, tazemetostat, and dexamethasone showed early activity and a tolerable safety profile in highly refractory multiple myeloma patients, with an overall response rate of 53.3%. No new safety signals were identified, and the regimen's efficacy was observed in patients who had received prior CAR T-cell therapy or bispecific T-cell engagers.

Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.